Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.

Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS.

Mol Cancer Res. 2018 May;16(5):754-766. doi: 10.1158/1541-7786.MCR-17-0614. Epub 2018 Mar 27.

PMID:
29588330
2.

Role of Dopamine Receptors in the Anticancer Activity of ONC201.

Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS.

Neoplasia. 2018 Jan;20(1):80-91. doi: 10.1016/j.neo.2017.10.002. Epub 2017 Dec 5.

3.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

PMID:
29157092
4.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS.

Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.

5.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS.

Cancer Res. 2017 Dec 15;77(24):6902-6913. doi: 10.1158/0008-5472.CAN-17-1767. Epub 2017 Oct 23.

PMID:
29061672
6.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.

PMID:
28886275
7.

Circulating tumor cells: silent predictors of metastasis.

Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK.

F1000Res. 2017 Aug 14;6. pii: F1000 Faculty Rev-1445. doi: 10.12688/f1000research.11313.1. eCollection 2017. Review.

8.

CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA.

Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS.

Cell Cycle. 2018;17(5):557-567. doi: 10.1080/15384101.2017.1346762. Epub 2018 Feb 19.

PMID:
28749203
9.

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS.

Cell Cycle. 2017 Jun 18;16(12):1193-1200. doi: 10.1080/15384101.2017.1320005. Epub 2017 May 9.

10.

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS.

Mol Cancer Ther. 2017 Jul;16(7):1290-1298. doi: 10.1158/1535-7163.MCT-17-0121. Epub 2017 Apr 19.

11.

Discovery and clinical introduction of first-in-class imipridone ONC201.

Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.

Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review.

12.

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS.

Sci Signal. 2016 Feb 16;9(415):ra18. doi: 10.1126/scisignal.aac4374.

13.

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

Prabhu VV, Hong B, Allen JE, Zhang S, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Res. 2016 Apr 1;76(7):1989-99. doi: 10.1158/0008-5472.CAN-14-2430. Epub 2016 Jan 12.

14.

The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.

Crowder RN, Dicker DT, El-Deiry WS.

J Biol Chem. 2016 Mar 11;291(11):5960-70. doi: 10.1074/jbc.M115.713545. Epub 2016 Jan 12.

15.

A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells.

Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS.

Oncotarget. 2016 Jan 26;7(4):3662-76. doi: 10.18632/oncotarget.6657.

16.

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS.

Cancer Res. 2015 Sep 15;75(18):3842-52. doi: 10.1158/0008-5472.CAN-13-1079. Epub 2015 Aug 20.

17.

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Talekar MK, Allen JE, Dicker DT, El-Deiry WS.

Cell Cycle. 2015 Aug 3;14(15):2422-8. doi: 10.1080/15384101.2015.1054086. Epub 2015 Jun 1.

18.

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.

Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.

19.

Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques.

Kaifi JT, Kunkel M, Das A, Harouaka RA, Dicker DT, Li G, Zhu J, Clawson GA, Yang Z, Reed MF, Gusani NJ, Kimchi ET, Staveley-O'Carroll KF, Zheng SY, El-Deiry WS.

Cancer Biol Ther. 2015;16(5):699-708. doi: 10.1080/15384047.2015.1030556.

20.

Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.

Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS.

Cancer Biol Ther. 2015;16(5):709-13. doi: 10.1080/15384047.2015.1030555.

21.

Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver.

Kaifi JT, Kunkel M, Dicker DT, Joude J, Allen JE, Das A, Zhu J, Yang Z, Sarwani NE, Li G, Staveley-O'Carroll KF, El-Deiry WS.

Cancer Biol Ther. 2015;16(5):690-8. doi: 10.1080/15384047.2015.1026508.

22.

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Prabhu VV, Allen JE, Dicker DT, El-Deiry WS.

Cancer Res. 2015 Apr 1;75(7):1423-32. doi: 10.1158/0008-5472.CAN-13-3451. Epub 2015 Feb 20.

23.

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS.

Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.

24.

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.

Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS.

Oncotarget. 2014 Dec 30;5(24):12728-37.

25.

Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report.

Patel AS, Allen JE, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS.

Oncol Lett. 2014 Jun;7(6):2110-2112. Epub 2014 Mar 24.

26.

COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.

Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS.

Cancer Res. 2014 May 1;74(9):2385-90. doi: 10.1158/0008-5472.CAN-13-2660. Epub 2014 Mar 10.

27.

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs.

Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS.

Oncotarget. 2014 Apr 15;5(7):1753-60.

28.

Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.

Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS.

Cancer Res. 2014 Feb 15;74(4):1153-65. doi: 10.1158/0008-5472.CAN-13-0955. Epub 2013 Nov 18.

29.

CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth.

Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS.

Cell Cycle. 2013 Dec 1;12(23):3689-701. doi: 10.4161/cc.26930. Epub 2013 Oct 25.

30.

Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients.

Kaifi JT, Kunkel M, Zhu J, Dicker DT, Gusani N, Yang Z, Sarwani NE, Li G, Kimchi ET, Staveley-O'Carroll KF, El-Deiry WS.

Cancer Biol Ther. 2013 Dec;14(12):1174-81. doi: 10.4161/cbt.26884. Epub 2013 Oct 23.

31.

Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells.

Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY.

Clin Chem. 2014 Feb;60(2):323-33. doi: 10.1373/clinchem.2013.206805. Epub 2013 Oct 16.

32.

Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.

PLoS One. 2013 Sep 26;8(9):e75414. doi: 10.1371/journal.pone.0075414. eCollection 2013.

33.

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS.

PLoS One. 2013;8(3):e59380. doi: 10.1371/journal.pone.0059380. Epub 2013 Mar 12. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aaa12360-0c90-42c3-bc43-d00022b68b81.

34.

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS.

Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.

35.

Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS.

Mol Cancer Ther. 2012 Nov;11(11):2321-30. doi: 10.1158/1535-7163.MCT-12-0578. Epub 2012 Sep 10.

36.

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.

Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS.

Cell Cycle. 2012 Sep 1;11(17):3312-23. doi: 10.4161/cc.21670. Epub 2012 Aug 16.

37.

Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.

Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS.

Mol Cancer Ther. 2012 Oct;11(10):2087-95. doi: 10.1158/1535-7163.MCT-12-0366. Epub 2012 Jul 16.

38.

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS.

Oncotarget. 2011 Oct;2(10):752-60.

39.

High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors.

Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS.

Am J Pathol. 2011 Nov;179(5):2169-76. doi: 10.1016/j.ajpath.2011.07.028. Epub 2011 Oct 3.

40.

Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):335-48. Epub 2011 Aug 15.

PMID:
21785270
41.

Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor.

Dicker DT, Kahn N, Flaherty KT, Lerner J, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):326-34. Epub 2011 Aug 15.

PMID:
21768778
42.

Spectral imaging-based methods for quantifying autophagy and apoptosis.

Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):349-56. Epub 2011 Aug 15.

43.

Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.

Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 1;12(3):239-51. Epub 2011 Aug 1.

PMID:
21725213
44.

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 1;12(3):229-38. Epub 2011 Aug 1.

PMID:
21725212
45.

Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab.

Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS.

Cell Cycle. 2011 Jul 15;10(14):2331-8. Epub 2011 Jul 15.

46.

Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.

Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS.

J Clin Oncol. 2011 Jul 20;29(21):2946-7; author reply 2947-8. doi: 10.1200/JCO.2011.36.6179. Epub 2011 Jun 20. No abstract available.

PMID:
21690466
47.

Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.

Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS.

Sci Transl Med. 2011 Jun 8;3(86):86ra50. doi: 10.1126/scitranslmed.3001384.

48.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS.

Cancer Res. 2011 Aug 1;71(15):5265-75. doi: 10.1158/0008-5472.CAN-11-1383. Epub 2011 Jun 6.

49.

The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.

Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS.

Cell Cycle. 2009 Dec 15;8(24):4168-75.

50.

Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.

Navaraj A, Finnberg N, Dicker DT, Yang W, Matthew EM, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2417-44. Epub 2009 Dec 14.

Supplemental Content

Loading ...
Support Center